Today, #FlagshipFounded# @moderna_tx, along with @Merck released positive results from its Phase 3 INTerpath-001 study for intismeran autogene, an investigational mRNA-based individualized neoantigen therapy, plus KEYTRUDA®, in patients with completely resected stage IIB-IV melanoma. 
Data will be presented at the 2026 European Society for Medical Oncology (@myESMO) Congress. #BiggerLeaps#

Flagship Founder and CEO @NoubarAfeyan joined @LizClaman on @FoxBusiness’ The Claman Countdown to discuss the Phase 3 trial data for @Merck and #FlagshipFounded# @moderna_tx’s mRNA-based therapy for melanoma. The results mark the first positive Phase 3 trial for an individualized neoantigen therapy and for an mRNA-based cancer therapy — a major milestone for personalized cancer treatment. Watch the full conversation here:

How a T cell killing a B cell in a petri dish turns into a strategic collaboration between J&J and #FlagshipFounded# @SailBiomeds to develop in vivo CAR-T: @AvakK, President of Flagship Labs and Co-Founder of Sail Biomedicines, reflects on the origins and potential impact of eRNA-based therapies. Read more here:

"It's really hard to envision extraordinary outcomes unless you do unreasonable-seeming things." In a new @business feature, Flagship Founder & CEO @NoubarAfeyan reflects on Flagship’s approach to company creation: pursuing ambitious scientific questions early, building the capabilities to test them, and creating companies around discoveries that can reshape what is possible. It's the approach that's led to over 130 companies, including #FlagshipFounded# @moderna_tx, @generate_biomed, @SailBiomeds, and more. #BiggerLeaps# Read the full story here:

Pioneering starts before there’s proof. Avak Kahvejian, President of Flagship Labs, reflects on taking a risk on an idea no one knew would work, and how eRNA went from a biological curiosity to a strategic collaboration between #FlagshipFounded# @SailBiomeds and @JNJNews: